Cullen/Frost Bankers’s CRISPR Therapeutics CRSP Stock Holding History

Cullen/Frost Bankers’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-10	Closed	-$454	–	1048
2023 Q3	$454	Hold	10	–	–	﹤0.01%	1128
2023 Q2	$561	Hold	10	–	–	﹤0.01%	1098
2023 Q1	$452	Hold	10	–	–	﹤0.01%	1171
2022 Q4	$407	Hold	10	–	–	﹤0.01%	1087
2022 Q3	$1K	Hold	10	–	–	﹤0.01%	1078
2022 Q2	$1K	Hold	10	–	–	﹤0.01%	1026
2022 Q1	$1K	Hold	10	–	–	﹤0.01%	1089
2021 Q4	$1K	Hold	10	–	–	﹤0.01%	1109
2021 Q3	$1K	Hold	10	–	–	﹤0.01%	1175
2021 Q2	$2K	Hold	10	–	–	﹤0.01%	1156
2021 Q1	$1K	Hold	10	–	–	﹤0.01%	1036
2020 Q4	$2K	Hold	10	–	–	﹤0.01%	1003
2020 Q3	$1K	Buy	+10	New	+$887	﹤0.01%	1071

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Cullen/Frost Bankers's CRSP Position: Q4 2023 in Review

Cullen/Frost Bankers sold out of CRISPR Therapeutics (CRSP) in Q4 2023, closing a stake of 10 shares — an estimated $454 sold.

Cullen/Frost Bankers first reported a position in CRSP in Q3 2020 and held it in 13 quarters. The position peaked at $2K in Q2 2021. 472 funds tracked by Wall St. Rank hold CRSP as of Q4 2023.

Cullen/Frost Bankers reported no remaining CRISPR Therapeutics position as of Q4 2023 after selling out during the quarter.
Cullen/Frost Bankers sold 10 CRISPR Therapeutics shares in Q4 2023, an estimated $454.
Cullen/Frost Bankers first reported a position in CRISPR Therapeutics in Q3 2020 and held it in 13 quarters.
Cullen/Frost Bankers's CRISPR Therapeutics position peaked at $2K in Q2 2021.
472 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2023.

Based on Cullen/Frost Bankers's 13F filing for Q4 2023, filed 6 Feb 2024.